Chinese pharmaceutical companies are developing next-generation obesity drugs that outperform placebos. Ecnoglutide, a GLP-1 receptor agonist, shows significant weight loss results in a phase III trial. Participants receiving weekly injections lost up to 13.8 kilograms over 48 weeks, while placebo recipients only lost about 200 grams. At the highest dose, 92.8% of ecnoglutide users lost at least 5% of their body weight. Ecnoglutide uniquely targets cyclic adenosine monophosphate, aiding in blood-sugar control and weight management.
The results from a phase III trial of ecnoglutide show that people receiving a weekly injection of the drug lost up to 13.8 kilograms over 48 weeks of treatment.
At the maximum dose of 2.4 milligrams, 92.8% of people lost at least 5% of their body weight, compared with 14% of people receiving placebo injections.
Ecnoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist analogue, similar to the blockbuster obesity drug semaglutide.
These drugs mimic the hormone GLP-1, which is involved in regulating appetite and managing blood-sugar levels.
Collection
[
|
...
]